The courtroom handed Eli Lilly a clean victory Monday, and the timing could not be better positioned. U.S. District Judge Zahid Quraishi ruled that Lilly can continue making disputed superiority claims in its ads while Novo Nordisk proceeds with its underlying lawsuit in federal court in Trenton, New Jersey. The judge called Novo’s claim of irreparable harm “inadequate to warrant the extraordinary relief it seeks.” The injunction bid is gone. The ads keep running.

Novo had sued in July, arguing that Lilly’s commercials for Zepbound and Mounjaro violated false advertising laws by comparing higher doses of those products with lower doses of Wegovy and Ozempic. One ad said people using Zepbound lost an average of 50 pounds versus 33 pounds for Wegovy users, with a written disclaimer. What the ruling does not resolve is the central dispute: the court made no finding on whether the advertisements are misleading, so the decision neither validates Lilly’s claims nor delivers a final rejection of Novo’s allegations. The underlying suit proceeds. But for the next several months, the ads stay.

That matters commercially because the timing is pointed. Open enrollment is underway. New-year prescribing season follows in January. Novo is working to regain U.S. market share in injectable obesity drugs, in a market projected to exceed $100 billion by the end of the decade. Lilly’s superiority messaging runs uncontested into exactly the window when patients and physicians are making formulary decisions. Zepbound already captured about 59.5% of the overall U.S. obesity market, based on IQVIA prescription data cited in recent industry reporting. A competitor trying to claw back share, blocked from silencing the comparison ads, is a competitor fighting uphill.

The Business Behind the Headlines

Lilly’s growth has been primarily fueled by Mounjaro and Zepbound. In the first half of 2026, Mounjaro and Zepbound accounted for 65% of Lilly’s total revenue, according to the company’s midyear filing. The court ruling is a marketing win. The financial scoreboard arrives two days from now. Investors will closely monitor performance when LLY reports third-quarter results on October 29.

Analysts expect revenue of $22.49 billion and EPS of $7.11 for Q3. Goldman Sachs expects Lilly to beat estimates and raise its outlook, citing stronger-than-consensus Mounjaro growth outside the U.S. and volume gains for Zepbound supported by Medicare’s GLP-1 Bridge program. Context makes this expectation credible: Lilly has been beating consensus in recent quarters.

The earnings setup has been building for weeks. Lilly’s revenue trajectory and the mechanics of why its October 29 report moves the stock are worth understanding before the number lands.

Investors will also watch Foundayo, the oral GLP-1 launched in April that generated $98 million in its first full quarter of sales. Eligible Medicare beneficiaries gained access through the Medicare GLP-1 Bridge program on July 1, making Q3 the first full quarter with that additional channel.

What Could Go Wrong

Valuation is the most honest concern. Morningstar’s fair value estimate has been cited at $870 per share in 2026 commentary, and the stock has traded above that level at times. The company’s market capitalization has climbed to roughly $1.14 trillion. At that scale, even strong growth gets discounted quickly if guidance merely meets rather than exceeds the highest estimates on the Street. Last quarter Lilly guided to $85 billion to $87 billion in 2026 revenue. Anything short of a raise on Thursday will disappoint.

The lawsuit itself remains a longer-term overhang. Novo has not dropped its false advertising claims, and a trial court ruling on the merits could eventually force Lilly to modify its comparative marketing. Emerging competition from Viking Therapeutics and Amgen’s obesity pipeline also means Lilly’s market share lead is not permanent, just well-defended for now.

The competitive picture extends beyond the lawsuit. Foundayo’s approval as the only GLP-1 pill with no food or water restrictions opens a patient segment injectable rivals cannot easily reach.

The Bottom Line

Monday’s ruling is not a footnote. It locks in Lilly’s marketing advantage during the highest-stakes prescribing window of the year and removes a near-term regulatory friction at precisely the moment institutional positioning around Q3 earnings is peaking. The ad war matters, but the earnings report on Thursday is where the stock actually moves. A run of recent beats, a bullish Goldman Sachs call, majority U.S. obesity market share in recent prescription data, and a fresh court win all point in the same direction. The counterargument is valuation, not fundamentals. For investors willing to own quality at a premium into a catalyst, LLY remains the clearest momentum name in the GLP-1 space right now.